Liver cancer: which patients benefit from immunotherapy?

(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) To date, physicians have been unable to predict which patients suffering from liver cancer would benefit from immunotherapy using checkpoint inhibitors and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an experimental model, this type of immunotherapy actually promoted the development of liver cancer, as now reported in the journal Nature.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news